Vanguard Capital Management
UNCY icon

Vanguard Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Vanguard Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.03M Buy
1,071,481
+260,051
+32% +$1.92M ﹤0.01% 3120
2026
Q1 		$5.34M Buy
+811,430
New +$5.32M ﹤0.01% 3036

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

Vanguard Capital Management's UNCY Position: Q2 2026 in Review

Vanguard Capital Management increased its Unicycive Therapeutics (UNCY) stake by 32% in Q2 2026, buying an estimated $1.92M and bringing the position to 1,071,481 shares worth $5.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

Vanguard Capital Management first reported a position in UNCY in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.34M in Q1 2026. 78 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Vanguard Capital Management held 1,071,481 shares of Unicycive Therapeutics worth $5.03M as of Q2 2026.
  • Vanguard Capital Management bought 260,051 Unicycive Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Unicycive Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3120 holding.
  • Vanguard Capital Management first reported a position in Unicycive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Unicycive Therapeutics position peaked at $5.34M in Q1 2026.
  • 78 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.